Research Paper Volume 13, Issue 1 pp 450—459

Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis

The PRISMA flow chart summarizing the identification process of eligible studies. WHO ICTRP, World Health Organization International Clinical Trials Registry Platform; PARPi, PARP inhibitor; RCT, randomized controlled trial.

Figure 1. The PRISMA flow chart summarizing the identification process of eligible studies. WHO ICTRP, World Health Organization International Clinical Trials Registry Platform; PARPi, PARP inhibitor; RCT, randomized controlled trial.